DURHAM, N.C. and PARIS--(BUSINESS WIRE)--Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The presentations contained important results, including a favorable safety profile for AGS-004, the ability to induce partial to complete viral load control in the absence of antiretroviral therapy (ART) during a 12-week structured treatment interruption (STI), and a potent and diverse immune response to AGS-004 treatment. These AGS-004 results are unprecedented for an immunotherapeutic candidate in HIV and, if confirmed in an upcoming randomized study, could lead to a new treatment paradigm for HIV.
